BioTime forms new acquisitions arm
BioTime has established a new subsidiary to oversee its strategic acquisitions.
BioTime has announced the formation of a new sub-division dedicated to pursuing opportunities for acquisitions in the fields of stem cells and regenerative medicines.
The biopharma company specialises in research and development of new products in these fields and has appointed Dr Thomas Okarma as chief executive of BioTime Acquisition Corporation.
Since 2010, the company has expanded the size of its business through a number of strategic acquisitions. These include ES Cell International, a Singapore-based company that developed the first human embryonic stem cells under current good manufacturing practices.
The company has also acquired Cell Cure Neurosciences, which develops therapeutic products derived from stem cells to treat retinal and neural degenerative diseases.
It is hoped that the specialised subsidiary will further the company's expansion through such acquisitions as these.
"Global advances on multiple fronts of stem cell biology have established the foundation for an integrative business approach to consolidate and translate these discoveries into products that may revolutionise clinical medicine," said Dr Okarma.
He added that "living cell therapies" can now be manufactured scalably and efficiently, as well as being tested in controlled clinical trials.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...